AMNEAL PHARMACEUTICALS, INC.
Ownership & governance
Executives 5Directors 10Avg age 61Avg tenure 6.5y
CP
Chirag K. Patel
Chief Executive Officer
Age 59Since 2019-07-31Profile →
+14
Executives5
CP
Chirag K. Patel→
Chief Executive Officer
Age 59Since 2019-07-31
CP
Chintu Patel→
Chief Executive Officer
Age 54Since 2019-07-31
AK
Anastasios Konidaris→
Director of Finance/CFO
Age 58Since 2023-11-06
SR
Sandeep R. Raktate→
Chief Operating Officer
—Since 2024-03-31
SK
Srinivas Kone→
Chief Tech/Sci/R&D Officer
—Since 2004-12-31
Board of directors10
DA
Deborah Autor→
Director/Board Member
Age 59Since 2023-11-06
JB
J. Buchi→
Director/Board Member
Age 70Since 2023-11-06
JG
Jeffrey George→
Director/Board Member
Age 52Since 2023-11-06
JK
John Kiely→
Director/Board Member
Age 67Since 2023-11-06
PM
Paul Meister→
Chairman
Age 73Since 2023-11-06
TN
Ted Nark→
Director/Board Member
Age 67Since 2023-11-06
CP
Chintu Patel→
Chairman
Age 54Since 2018-04-30
CP
Chirag K. Patel→
Director/Board Member
Age 59Since 2001-12-31
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Tushar Patel | 16.79 % | 53,578,209 |
| Chintu Patel | 8.194 % | 26,141,773 |
| BlackRock Advisors LLC | 7.298 % | 23,281,121 |
| Chirag K. Patel | 7.104 % | 22,662,890 |
| Akram Mahesh | 5.706 % | 18,202,546 |
Catalog · 2026-07-09
Registry officers15
| Name | Role | Since | Shares |
|---|---|---|---|
| Anastasios Konidaris | Director of Finance/CFO | 2023-11-06 | - |
| Chintu Patel | Chief Executive Officer | 2019-07-31 | - |
| Chintu Patel | Chairman | 2018-04-30 | - |
| Chirag K. Patel | Chief Executive Officer | 2019-07-31 | - |
| Paul Meister | Chairman | 2023-11-06 | - |
| Sandeep R. Raktate | Chief Operating Officer | 2024-03-31 | - |
| Srinivas Kone | Chief Tech/Sci/R&D Officer | 2004-12-31 | - |
| Chirag K. Patel | Director/Board Member | 2001-12-31 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 22.71Range 20–27Analysts 7
20Mean 22.7127
- Strong buy 3
- Buy 4
Broker actions40 of 72
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Oppenheimer | Initiated | Outperform | 27 | 2026-09-23 |
| Barclays | Maintained | Overweight | 20 | 2026-09-17 |
| Leerink Partners | Initiated | Outperform | 23 | 2026-09-09 |
| UBS | Maintained | Buy | 25 | 2026-08-03 |
| UBS | Maintained | Buy | 23 | 2026-07-15 |
| Barclays | Maintained | Overweight | 16 | 2026-05-20 |
| UBS | Initiated | Buy | 19 | 2026-04-17 |
| Truist Securities | Maintained | Buy | 17 | 2026-03-02 |
| Barclays | Initiated | Overweight | 15 | 2025-12-09 |
| Piper Sandler | Reiterated | Overweight | 13 | 2025-10-31 |
| JP Morgan | Maintained | Overweight | 14 | 2025-09-16 |
| Barclays | Maintained | Overweight | 11 | 2025-03-03 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.